PetMeds Q4 net sales down 15.6% YoY to $42.8mln, net loss $4.1mln.

• PetMeds Q4 net sales $42.8mln, down 15.6% YoY. • Prescription medication sales decline drive the decrease. • Net loss of $4.1mln, compared to $11.6mln in the prior year. • General and administrative expenses lower. • Trade name impairment charge absent. • Interest income higher.

PetMeds, Inc. reported Q4 net sales of $42.8 million, reflecting a 15.6% year-over-year decline, primarily attributed to a decrease in prescription medication sales. The company experienced a net loss of $4.1 million for the quarter, a significant improvement compared to the $11.6 million net loss in the same period of the previous year. This reduction in the net loss was partly due to lower general and administrative expenses, which contributed positively to the company's financial performance. Notably, the absence of a trade name impairment charge also played a role in the improved financial outcome. Additionally, interest income saw an increase, further supporting the reduction in the net loss. These factors collectively indicate a more controlled cost environment and improved operational efficiency, despite the challenging market conditions affecting prescription medication sales.